Ideaya Biosciences stock (US45166A1025): Positioned in iShares Genomics ETF holdings

Ideaya Biosciences, a clinical-stage precision oncology company, maintains a notable presence in the iShares Genomics Immunology and Healthcare ETF (IDNA) with a 2.61% weighting and 149,434 shares held, according to StockAnalysis.com as of 2026. The company's focus on synthetic lethality-based therapies positions it within key biotech investment vehicles tracking genomics and immunotherapy sectors.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Ideaya Biosciences: core business model

Ideaya Biosciences develops precision medicines targeting oncology through synthetic lethality mechanisms. The company leverages proprietary technologies like its SNIPR Platform to identify tumor-specific vulnerabilities, aiming to deliver therapies with high therapeutic indices. Headquartered in the US, Ideaya advances a pipeline including IDE397, a MAT2A inhibitor in Phase 2 trials for solid tumors, as detailed on its investor relations site as of 2026.

Synthetic lethality targets cancer cells while sparing healthy ones, a strategy validated in approved drugs like PARP inhibitors. Ideaya's approach emphasizes biomarker-driven patient selection to maximize response rates, aligning with trends in personalized medicine relevant to US investors tracking Nasdaq-listed biotechs.

Main revenue and product drivers for Ideaya Biosciences

Pipeline progression drives value, with key assets like darovasertib (PKC inhibitor) in combination trials for uveal melanoma and IDE261 (MTAP deletion target) advancing clinically. Partnerships, such as with GSK for preclinical assets, provide non-dilutive funding and milestone potential. Future revenue hinges on regulatory milestones and commercialization, typical for clinical-stage biotechs.

Ideaya's inclusion in the IDNA ETF underscores its role in genomics-focused portfolios, with a 2.61% allocation signaling exposure to immunotherapy and genetic targeting innovations, per StockAnalysis.com as of 2026. This positioning aids US investors seeking diversified biotech plays.

Industry trends and competitive position

The precision oncology market grows with advances in genomic profiling, where Ideaya competes with players like Repare Therapeutics and BeiGene in synthetic lethality. US market leadership in biotech innovation benefits firms like Ideaya, with Nasdaq listings facilitating institutional access. ETF inclusions like IDNA highlight competitive standing in genomics subsectors.

Conclusion

Ideaya Biosciences continues to advance its precision oncology pipeline, with ETF holdings reflecting sector interest. US investors gain exposure via Nasdaq listing and genomics-focused funds like IDNA. Developments remain tied to clinical outcomes and partnerships in a competitive biotech landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.